派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

已收盘 07-07 16:08:40

5.680

+0.190

+3.46%

最高6.250	最低5.340	成交量1,985万
今开5.510	昨收5.490	日振幅16.58%
总市值22.21亿	流通市值21.92亿	总股本3.91亿
成交额1.16亿	换手率5.14%	流通股本3.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":5.68,"timestamp":1783411720008,"preClose":5.49,"halted":0,"volume":19847750,"delay":0,"changeRate":0.03460837887067386,"floatShares":386000000,"shares":391000000,"eps":-0.55,"marketStatus":"已收盘","change":0.19,"latestTime":"07-07 16:08:40","open":5.51,"high":6.25,"low":5.34,"amount":116379168,"amplitude":0.165756,"askPrice":5.69,"askSize":1250,"bidPrice":5.68,"bidSize":30400,"shortable":3,"etf":0,"ttmEps":-0.612785,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783474200000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":5.49,"openAndCloseTimeList":[[1783387800000,1783396800000],[1783400400000,1783411200000]],"volumeRatio":1.324667,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565","defaultTab":"news","newsList":[{"id":"1139784250","title":"派格生物医药-B更新2026年6月股份变动月报表，注册股本增至391,091,532股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139784250","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139784250?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:51","pubTimestamp":1783327878,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年7月6日披露2026年6月股份变动月报表，报告期为截至2026年6月30日。公告显示，本月公司H股及非上市股份均有相应变动。公司披露，101,702,051股非上市股份已于2026年6月25日完成转为H股，并自2026年6月26日起在香港联交所上市。上述变动后，公司本月底注册股本合计为391,091,532股。\\n\\n本次月报由联席公司秘书黄一峰签署，并披露于香港联交所。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648571593","title":"港股异动 | 派格生物医药-B(02565)涨超5% 维培那肽注射液通过26年国家医保目录调整初步形式审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2648571593","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648571593?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:39","pubTimestamp":1782970769,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨4.13%，报5.55港元，成交额3902.16万港元。消息面上，近日，派格生物医药-B发布公告，本集团核心产品维培那肽注射液已被列入国家医疗保障局公布的《2026年国家基本医疗保险、工伤保险和生育保险药品目录及商保创新药目录调整通过初步形式审查的申报药品名单》，位列“目录外西药和中成药-基本目录”第242项，药品类别为西药，通过申报条件为“目录外条件1”，并标注为独家品种。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462207.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","161726","BK4585","XBI","BK1161","BK4588","399441","02565","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648516571","title":"港股异动 | 派格生物医药-B(02565.HK)涨超5% 维培那肽注射液通过26年国家医保目录调整初步形式审查","url":"https://stock-news.laohu8.com/highlight/detail?id=2648516571","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648516571?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:39","pubTimestamp":1782970769,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134493843","title":"异动解读｜派格生物医药-B盘中下跌8.3%，H股全流通完成后股价持续剧烈震荡","url":"https://stock-news.laohu8.com/highlight/detail?id=1134493843","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134493843?lang=zh_cn&edition=full","pubTime":"2026-06-30 10:46","pubTimestamp":1782787568,"startTime":"0","endTime":"0","summary":"6月30日，派格生物医药-B盘中下跌8.3%，报5.3港元/股，成交额2587.32万港元。消息面上，公司于6月25日完成H股全流通，约1.02亿股非上市股份转换为H股并于6月26日起上市交易，H股占比由72.69%升至98.70%。受大量此前受限股份集中获得流通资格影响，股价于6月26日大跌创出历史新低4.96港元，6月29日虽自低位反弹涨逾17%，但今日再度回落，显示新增流通筹码的抛压尚未完全消化，短期内股价仍处于剧烈波动阶段。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647324070","title":"港股收评：恒指、恒科大举反弹，创新药、半导体爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=2647324070","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647324070?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:33","pubTimestamp":1782722022,"startTime":"0","endTime":"0","summary":"6月29日，香港恒生指数收涨1.57%，恒生科技指数收涨3.23%。盘面上，创新药概念全天爆发，抗肿瘤、生物医疗、AI医疗、养老产业、医美等方向活跃。医药生物、家电、军工、传媒、食品饮料、软件服务、非银金融等板块涨幅居前；机械、建材、钢铁等少数板块下跌。具体来看，科网股方面，网易涨超6%，携程集团、百度集团、美团、哔哩哔哩、阿里巴巴、京东集团、快手等集体上涨。据此操作，风险自担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"fenghuang_stock","url":"https://finance.ifeng.com/c/8uM0PWbWCwR","rn_cache_url":null,"customStyle":"","selectors":"article, body","filters":"","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.ifeng.com/c/8uM0PWbWCwR","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["03032","03115","03423","HSTECH","03088","82800","07226","07500","03067","83115","HHImain","HSI","BK1161","MCHmain","02800","02833","09067","09115","513600","03419","03037","07552","07200","MHImain","02837","03417","03033","09088","02565","07300"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647564324","title":"港股收评：恒生科技指数收涨3.23% 生物医药板块领涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2647564324","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647564324?lang=zh_cn&edition=full","pubTime":"2026-06-29 16:15","pubTimestamp":1782720956,"startTime":"0","endTime":"0","summary":"南方财经6月29日电，香港恒生指数收涨1.57%，恒生科技指数收涨3.23%。生物医药板块领涨，药捷安康-B涨超39%，派格生物医药-B涨超16%，荣昌生物涨超14%，恒瑞医药涨超9%；半导体板块走强，兆易创新涨超14%，华虹宏力涨超7%，上海复旦涨超7%。PCB概念下挫，建滔集团跌超5%，广合科技跌超4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606293786652712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07200","02800","09115","82800","07300","83115","03115","03417","MCHmain","513600","02565","HHImain","07552","07500","BK1161","03037","03032","HSI","03419","03088","HSTECH","02833","07226","MHImain","03067","09088","09067","03423","02837","03033"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172146879","title":"异动解读｜派格生物医药-B盘中上涨17.94%，H股全流通完成后股价低位反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1172146879","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172146879?lang=zh_cn&edition=full","pubTime":"2026-06-29 11:08","pubTimestamp":1782702484,"startTime":"0","endTime":"0","summary":"6月29日，派格生物医药-B盘中上涨17.94%，报5.85港元/股，成交额9653.63万港元。消息面上，公司于6月25日完成H股全流通，约1.02亿股非上市股份转换为H股并于6月26日起上市交易，H股占比由72.69%升至98.70%。受大量此前受限股份集中获得流通资格影响，股价于6月26日大跌创出历史新低4.96港元。经过前一交易日集中抛压释放后，今日股价自低位出现明显反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646391443","title":"派格生物医药-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2646391443","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646391443?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:59","pubTimestamp":1782453588,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116822466","title":"异动解读｜派格生物医药-B盘中下跌8.19%，H股全流通完成逾1亿股新增上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=1116822466","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116822466?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:40","pubTimestamp":1782452415,"startTime":"0","endTime":"0","summary":"6月26日，派格生物医药-B盘中下跌8.19%，报5.27港元/股，成交额4107.95万港元。消息面上，公司公告H股全流通已完成，约1.02亿股非上市股份于6月25日完成转换为H股，并于6月26日上午九时起在联交所开始上市交易。转换完成后，H股数量由2.84亿股增至3.86亿股，占已发行股份总数比例由72.69%升至98.70%，非上市股份由1.07亿股骤降至509万股。大量此前受限股份集中获得流通资格，短期内显著增加了市场可交易筹码供给，对股价形成抛压。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646398763","title":"派格生物医药-B公布完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2646398763","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646398763?lang=zh_cn&edition=full","pubTime":"2026-06-26 13:39","pubTimestamp":1782452340,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　派格生物医药-B（02565）发布公告，1.02亿股非上市股份转换为H股已于2026年6月25日完成，而转换H股已于2026年6月26日上午九时正起在联交所开始上市。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-06-26/doc-inietfxy2012835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XBI","BK4581","02565","BK4588","BK1161","161726","BK4585","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166774264","title":"派格生物医药-B将101,702,051股非上市股份转为H股 占转换前股本26.0047%","url":"https://stock-news.laohu8.com/highlight/detail?id=1166774264","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166774264?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:12","pubTimestamp":1782447147,"startTime":"0","endTime":"0","summary":"派格生物医药（杭州）股份有限公司于2026年6月26日发布翌日披露报表，宣布将101,702,051股非上市股份转为H股。该部分股份约占转换前已发行股份总数的26.0047%，转换生效日期为2026年6月25日，并预计自2026年6月29日起在香港联交所上市。转换完成后，公司H股股本由284,300,339股增至386,002,390股，非上市股份为5,089,142股，公司库存股份数量为0股。公司确认，本次股份转换事项已获董事会正式授权，且符合香港联合交易所有限公司证券上市规则及其他相关法律法规的规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"派格生物医药-B将101,702,051股非上市股份转为H股 占转换前股本26.0047%","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100940830","title":"派格生物完成H股全流通 逾1亿股非上市股份转换上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1100940830","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100940830?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:07","pubTimestamp":1782446820,"startTime":"0","endTime":"0","summary":"派格生物医药-B（02565）公告，公司H股全流通已完成。101,702,051股非上市股份转换为H股的手续于2026年6月25日完成，转换后的H股自2026年6月26日上午九时起在联交所开始上市。\n转换完成后，公司股权结构发生变化。截至转换及上市完成后，H股数量由284,300,339股增至386,002,390股，占已发行股份总数的比例由72.69%升至98.70%；非上市股份数量由106,791,193股减至5,089,142股，占比由27.31%降至1.30%。公司已发行股份总数维持391,091,532股不变。\n公告提示，股东及潜在投资者在买卖公司H股时应审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"派格生物完成H股全流通 逾1亿股非上市股份转换上市","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646233519","title":"派格生物医药-B(02565.HK)完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2646233519","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646233519?lang=zh_cn&edition=full","pubTime":"2026-06-26 12:05","pubTimestamp":1782446732,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180055525","title":"异动解读｜派格生物医药-B盘中下跌8.23%，诉讼风险叠加行业弱势持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1180055525","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180055525?lang=zh_cn&edition=full","pubTime":"2026-06-16 11:46","pubTimestamp":1781581564,"startTime":"0","endTime":"0","summary":"6月16日，派格生物医药-B盘中下跌8.23%，报6.47港元/股，成交额3493.59万港元，股价再创52周新低。此外，公司自上市以来股价已从高位大幅回落，近3个月累计跌幅超过85%，市场情绪持续低迷。行业层面，生物科技板块整体走弱，康方生物跌6.21%、三生制药跌5.03%、信达生物跌1.81%，板块联动效应进一步加剧抛压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104416364","title":"异动解读｜派格生物医药-B盘中上涨8.37%，收到腾瑞制药商业化首笔权益金6100万港元提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1104416364","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104416364?lang=zh_cn&edition=full","pubTime":"2026-06-08 10:22","pubTimestamp":1780885322,"startTime":"0","endTime":"0","summary":"6月8日，派格生物医药-B盘中上涨8.37%，报8.4港元/股，成交额9318.64万港元。消息面上，公司6月5日晚间公告，已收到上海腾瑞制药支付的维培那肽注射液（派达康）在中国大陆地区商业化合作首笔权益金6100万港元，标志着双方合作进入实质履约及全面推进阶段。此外，近期公司CR059研究成果入选EASD口头发言环节、董事会提议回购不超过10%已发行H股、核心产品纳入医保参照药预沟通增补公示等多重利好共振，持续推动股价反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641720791","title":"港股异动 | 派格生物医药-B(02565)涨超6% 收到腾瑞制药维培那肽商业化首笔权益金6100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641720791","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641720791?lang=zh_cn&edition=full","pubTime":"2026-06-08 09:34","pubTimestamp":1780882478,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超6%，截至发稿，涨5.38%，报8.43港元，成交额3147.58万港元。消息面上，6月5日晚，派格生物发布自愿公告，公司已收到上海腾瑞制药支付的首笔商业化合作权益金港币6100万元。公告显示，该笔款项来自双方此前围绕派格生物自主研发的国家1类新药维培那肽注射液派达康在中国大陆地区商业化推广达成的合作安排。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451200.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","XBI","BK4581","VXUS","BK4588","161726","399441","BK1191","01477","BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641316114","title":"派格生物医药-B(02565)收到腾瑞制药维培那肽商业化首笔权益金6100万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641316114","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641316114?lang=zh_cn&edition=full","pubTime":"2026-06-05 18:08","pubTimestamp":1780654114,"startTime":"0","endTime":"0","summary":"智通财经APP讯，派格生物医药-B 发布公告，就有关本集团与上海腾瑞制药股份有限公司就本集团自主研发的国家1类新药维培那肽注射液(派达康)在中国大陆地区商业化推广达成合作安排。根据双方已签署的商业化合作协议，本集团已收到腾瑞制药支付的首笔权益金6100万港元。派达康为本集团自主研发并已获国家药品监督管理局批准上市的长效GLP-1受体激动剂，用于2型糖尿病治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450802.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","01477","02565","BK1161","BK4581","XBI","BK1574","BK4585","161726","399441","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109583007","title":"异动解读｜派格生物医药-B盘中上涨8.52%，多重利好共振延续反弹势头","url":"https://stock-news.laohu8.com/highlight/detail?id=1109583007","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109583007?lang=zh_cn&edition=full","pubTime":"2026-06-04 13:42","pubTimestamp":1780551720,"startTime":"0","endTime":"0","summary":"6月4日，派格生物医药-B盘中上涨8.52%，报8.79港元/股，成交额1.38亿港元。消息面上，公司近期连续释放多重利好。此外，核心产品维培那肽注射液已纳入医保参照药预沟通增补公示，医保准入预期持续强化。多重利好叠加前期解禁抛压释放充分，推动股价延续反弹。派格生物医药是一家深耕慢病代谢领域的生物科技公司，核心产品为长效GLP-1受体激动剂，主要用于治疗2型糖尿病及肥胖症等代谢疾病。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150523805","title":"派格生物医药-B更新2026年5月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150523805","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150523805?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:46","pubTimestamp":1780476394,"startTime":"0","endTime":"0","summary":"2026年6月3日，派格生物医药（杭州）股份有限公司公布2026年5月的证券变动月报表。本次报告期为截至2026年5月31日止的一个月，显示公司注册股本及已发行股份总数均未发生变化。截至5月31日，公司H股已发行股份数量为284,300,339股，非上市股份数量为106,791,193股，注册股本合计为391,091,532股。公司进一步确认，上市股份部分的公众持股比例符合香港联交所要求。截至报告期末，公司股本总数保持稳定。公告由联席公司秘书黄一峰签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640967369","title":"港股异动 | 派格生物医药-B(02565)涨超13% CR059获EASD 2026接收并入选口头讨论发言环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2640967369","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640967369?lang=zh_cn&edition=full","pubTime":"2026-06-02 10:06","pubTimestamp":1780365980,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超13%，截至发稿，涨9.8%，报8.75港元，成交额1.08亿港元。消息面上，6月1日，派格生物医药-B发布公告，集团自主研发的环状RNA编码GLP-1类似物CR059研究成果已获第62届欧洲糖尿病研究协会年会接收，并入选口头讨论发言环节。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161726","XBI","BK4581","VXUS","399441","BK4585","02565","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.0502},{"period":"1month","weight":-0.3137},{"period":"3month","weight":-0.8902},{"period":"6month","weight":-0.9265},{"period":"1year","weight":-0.5107},{"period":"ytd","weight":-0.9204}],"compareEarnings":[{"period":"1week","weight":0.0256},{"period":"1month","weight":-0.0539},{"period":"3month","weight":-0.0597},{"period":"6month","weight":-0.1074},{"period":"1year","weight":-0.0125},{"period":"ytd","weight":-0.0786}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}